Frey S E, Bollen W, Sizemore D, Campbell M, Curtiss R
Vaccine and Treatment Evaluation Unit, Saint Louis University Health Sciences Center, St. Louis, Missouri 63110, USA.
Clin Immunol. 2001 Oct;101(1):32-7. doi: 10.1006/clim.2001.5088.
Live attenuated chi8110 Salmonella enterica serovar Typhi ISP1820 vaccine was given in a dose-escalation trial to healthy, adult volunteers. Positive stool and blood cultures were noted, but limited, as were immune responses measured by ELISA and ELISPOT. Only volunteers with bacteremia developed immune responses; however, no symptoms were associated with bacteremia. The vaccine was insufficiently immunogenic for use as a vaccine. It is possible that reduced survival in the gut and reduced immunogenicity may have been due to the thawing of frozen inocula immediately prior to use.
减毒活伤寒沙门氏菌chi8110血清型Typhi ISP1820疫苗在一项剂量递增试验中给予健康成年志愿者。观察到粪便和血液培养呈阳性,但数量有限,通过酶联免疫吸附测定(ELISA)和酶联免疫斑点法(ELISPOT)测量的免疫反应也是如此。只有发生菌血症的志愿者产生了免疫反应;然而,菌血症未伴随任何症状。该疫苗作为一种疫苗使用时免疫原性不足。肠道内存活率降低和免疫原性降低可能是由于在使用前立即解冻冷冻接种物所致。